Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Agile Therapeutics shares plummet after contraceptive study data Agile Therapeutics Inc. AGRX, -43.40% shares plummeted in the extended session Tuesday even after the women's health company reported positive results in a study of its Twirla contraceptive patch. Agile shares dropped 73% to $1.33 after hours. Using the Pearl index, which is the number of times the contraceptive fails over a calculated 100 years of use, Twirla scored a 4.80 for its target population, but 51.4% of study participants had to discontinue the study. The FDA will have to review how Agile calculated the Pearl index results, the company said. Agile plans to resubmit its marketing application to the FDA in the first half of 2017. Read full article here: http://www.marketwatch.com/story/ag...met-after-contraceptive-study-data-2017-01-03
Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors PRINCETON, N.J., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit facility with Perceptive Advisors to provide Agile with up to $35 million through term loans in three tranches. $5 million was funded today after the satisfaction of customary closing conditions, $15 million will be available if Twirla® is approved by the U.S. Food and Drug Administration (“FDA”), and $15 million will be available upon the achievement of certain revenue milestones. Agile is permitted to make interest only payments on the loan until February 2023. Full article - https://www.globenewswire.com/news-...n-Loan-Facility-with-Perceptive-Advisors.html
